Dysregulation of type I interferon responses in COVID-19

Infection with SARS-CoV-2 can lead to excessive production of pro-inflammatory cytokines, but the production of type I interferons, which are key antiviral mediators, is reportedly blunted. Here, we discuss how imbalanced interferon responses may contribute to the pathology of COVID-19. In this Comm...

Full description

Saved in:
Bibliographic Details
Published inNature Reviews Immunology Vol. 20; no. 7; pp. 397 - 398
Main Authors Acharya, Dhiraj, Liu, GuanQun, Gack, Michaela U.
Format Journal Article Web Resource
LanguageEnglish
Published London Nature Publishing Group UK 01.07.2020
Nature Publishing Group
Springer Nature B.V
Subjects
631/250/127/1212
631/326/596/4130
Acute respiratory distress syndrome
Animals
Betacoronavirus - physiology
Biological response modifiers
Biomedical and Life Sciences
Biomedicine
Comment
Coronavirus Infections - drug therapy
Coronavirus Infections - immunology
Coronavirus Infections - pathology
Coronaviruses
COVID-19
Development and progression
Health aspects
Humans
Immunology
Inflammation
Interferon
Interferon Type I - immunology
Interferon-alpha - administration & dosage
Pandemics
Pathology
Pneumonia, Viral - drug therapy
Pneumonia, Viral - immunology
Pneumonia, Viral - pathology
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Online AccessGet full text

Cover

More Information
Summary:Infection with SARS-CoV-2 can lead to excessive production of pro-inflammatory cytokines, but the production of type I interferons, which are key antiviral mediators, is reportedly blunted. Here, we discuss how imbalanced interferon responses may contribute to the pathology of COVID-19. In this Comment, Michaela Gack and colleagues discuss how the dysregulation of type I interferon responses may contribute to COVID-19 pathology.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1474-1733
1474-1741
DOI:10.1038/s41577-020-0346-x